Joy Behar is taking some sick leave on "The View." The Emmy-winning host and comedian, 83, has been absent from back-to-back shows of the ABC daytime talk show after injuring her foot, Behar's cohost, ...

Whoopi Goldberg started Thursday’s episode of “The View” by calling the shooting death of Charlie Kirk “beyond devastating.” The conservative activist, Donald Trump ally and Turning Point USA ...

Whoopi Goldberg and Joy Behar returned to The View Season 29 this week, and they have no plans on retiring anytime soon. The longest-tenured ABC daytime co-hosts revealed in an interview why they are ...

Michael Block is a 14 time GLAM Award nominated writer, producer, and host of the podcast Block Talk. Throughout his time in the entertainment industry, he has worked on and off Broadway as a stage ...

The US FDA has granted De Novo marketing authorization for ArteraAI Prostate (Artera, Los Altos, California), a novel artificial intelligence (AI)-powered risk-stratification tool for patients with ...

“The View” panelists sharply disagreed on the reasons behind Donald Trump‘s victory in the 2024 Presidential election. In a Hot Topics segment from Friday’s episode, Joy Behar began by praising ...

Alyssa Farah Griffin, the former White House communications aide to Donald Trump, told her cohosts on ABC’s The View today that for the first time in her life she’s voted for a Democrat for president.

Prior to the 20 th Century, one of the most common ways of seeing the world was through the lens of stratification, which is the idea that the natural world comes in different scales or layers. For ...

Patients at higher grade of risk-stratification showed higher Lp(a) level. Participants with both high grades of Lp(a) and risk-stratification were at significantly high risk for recurrent CVEs. The ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating the ...

The researchers suggest certain refinements to the 2022 European LeukemiaNet classification model for patients aged 60 years or older receiving lower intensity treatment (LIT), including the adoption ...